The solution for intramuscular administration of Meloxicam DS contains the active substance meloxicam and is a analgesic, non-steroidal anti-inflammatory agent, a COX-2 inhibitor. It is used in the symptomatic treatment of joint diseases. Dispensed by prescription from a doctor. It is a generic in the active substance of drugs known under the trade name Movalis.
Active ingredient: meloxicam - 15 mg Excipients: ethanol; poloxamer 188; sodium chloride; glycine; meglumine; sodium hydroxide; water for injections
Indications / Application Notes
Symptomatic treatment: - osteoarthrosis; - rheumatoid arthritis; - Ankylosing spondylitis (Ankylosing spondylitis); - other inflammatory and degenerative diseases of the musculoskeletal system, such as arthropathy, dorsopathy (for example, sciatica, lower back pain, shoulder-shoulder periarthritis) accompanied by pain. The drug is intended for short-term symptomatic therapy, to reduce pain and inflammation at the time of use; on progression the disease is not affected.
-hypersensitivity to the active substance or auxiliary components; - the period after coronary artery bypass grafting; - decompensated heart failure; - a complete or incomplete combination of bronchial asthma, recurrent polyposis of the nasal mucosa and paranasal sinuses and intolerance to acetylsalicylic acid and other NSAIDs (including history); - erosive and ulcerative changes in the mucous membrane of the stomach and duodenum, active gastrointestinal bleeding; - exacerbation of inflammatory bowel disease (ulcerative colitis, Crohn's disease); - cerebrovascular bleeding or other bleeding; - severe liver failure or active liver disease; - severe renal failure in patients not undergoing dialysis (Cl creatine <30 ml / min), progressive kidney disease, including confirmed hyperkalemia; - pregnancy; - period of breastfeeding; - children's age up to 18 years.
From the digestive system:> 1% - dyspepsia, incl. nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea; 0.1–1% - transient increase in the activity of hepatic transaminases, hyperbilirubinemia, belching, esophagitis, gastroduodenal ulcer, gastrointestinal bleeding (including hidden), stomatitis; <0.1% - gastrointestinal perforation, colitis, hepatitis, gastritis. From the hemopoietic system:> 1% - anemia; 0,1–1% - change in blood count, including leukopenia, thrombocytopenia. From the skin:> 1% - itching, skin rash; 0.1–1% - urticaria; <0.1% - photosensitivity, bullous eruptions, erythema multiforme, incl. Stevens-Johnson syndrome, toxic epidermal necrolysis. From the respiratory system: <0.1% - bronchospasm. From the side of the central nervous system:> 1% - dizziness, headache; 0.1–1% - vertigo, tinnitus, drowsiness; <0.1% - confusion, disorientation, emotional lability. From the CCC:> 1% - peripheral edema; 0.1–1% - increased blood pressure, palpitations, flushing of the face. From the urinary system: 0.1–1% - hypercreatinemia and / or increased urea in the blood serum; <0.1% - acute renal failure; connection with the use of meloxicam has not been established - interstitial nephritis, albuminuria, hematuria. On the part of the sensory organs: <0.1% - conjunctivitis, visual impairment, including blurred vision. Allergic reactions: <0.1% - angioedema, anaphylactic / anaphylactoid reactions. Local reactions:> 1% - swelling at the injection site; <1% - pain at the injection site.
Caution should be exercised when using the drug in patients with a history of gastric or duodenal ulcer, as well as in patients undergoing anticoagulant therapy. Such patients have an increased risk of manifestly erosive gastrointestinal diseases. Caution should be exercised and renal function indicators monitored during the use of the drug in elderly patients, patients with heart failure with symptoms of circulatory failure, patients with cirrhosis, and patients with hypovolemia as a result of surgical interventions. In patients with renal failure, if Cl creatinine> 30 ml / min, dosage adjustment is not required. In patients on dialysis, the dosage of the drug should not exceed 7.5 mg / day. Patients taking both diuretics and meloxicam should take enough fluids. If during the treatment process allergic reactions (itching, skin rash, urticaria, photosensitivity) occur, you need to consult a doctor to decide whether to stop taking the drug. Meloxicam, like other NSAIDs, can mask the symptoms of infectious diseases. The use of meloxicam, as well as other drugs that block the synthesis of GHGs, can affect fertility, therefore it is not recommended for women planning a pregnancy. Driving vehicles, servicing machinery and mechanisms. The use of the drug can cause unwanted effects in the form of headache and dizziness, drowsiness. You should refuse to drive vehicles, servicing machines and mechanisms that require concentration.
Solution for intramuscular administration, 10 mg / ml (15 mg / 1.5 ml). 1.5 ml in a glass ampoule. 3 glass ampoules in a plastic contour tray. On 1 plastic contour pallet placed in a cardboard box.
In a dry, dark place, at a temperature of no higher than25 °C.
Zhangjiakou Kaiwei Pharmaceutical Co. Ltd. China